Antibiotic resistance tests; the bacteria in the culture on the left are sensitive to the antibiotics contained in the white paper discs. The bacteria on the right are resistant to most of the antibiotics. © Dr Graham Beards wikipedia.org
Financing

Novo Nordisk Foundation in US$25m partnership with CARB-X

Novo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.

Read more
© Jabri & Abadie Nat.Rev.Immunol 2015; Waldmann et al. J. Exp. Med 2019; Created with BioRender
M&A

Novartis AG to buy immunology specialist Calypso Biotech BV

Calypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up to US$175.

Read more
FDA Building 31 houses the Office of the Commissioner and the Office of Regulatory Affairs. © U.S. Food and Drug Administration
Obesity

GLP1 agonists: FDA investigates suicide risk

Following in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.

Read more
Boehringer Ingelheim headquarters. © Boehringer Ingelheim
Deal

Boehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.

Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from  Kyowa Kirin Co. Ltd.

Read more
Brown and white fat cells. © Patrick Seale, University of Pennsylvania School of Medicine/NIH
Financing

miRNA specialist Resalis Therapeutics Srl raises €10m in Series A financing

Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.

Read more
EM picture of A. baumannii. © Vader1941 - wikipedia.org
AMR

Roche presents restistance-breaking antibiotic

Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.

Read more
In Berlin-Spandau on the site of the historical Prussian rifle factory from the 19th century, HAVEL LABS is emerging as a Work-Life-Place of the future, precisely tailored to the requirements of companies in the Life Science sector. Picture: © bloomimages

The future finds a new home: HAVEL LABS

With HAVEL LABS, a unique campus is being developed in Berlin-Spandau. ­Spanning over 20,000 m2, this space is designed for forward-thinking work environments. Modern industrial workplaces and logistics concepts, aligned with GMP (Good Manufacturing Practice) ­guidelines, can be ­effortlessly realised on the premises, as can laboratories ranging from safety level S1 to S3 in ­accordance with German Genetic Engineering Safety Regulations.

Read more
Alfasigma manufacturing plant. © N. Biddau/Alfasigma SpA
Collaboration

Alfasigma SpA signs €170m deal with Galapagos NV

Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal.

Read more
European Biotechnology Guide

Next European Biotechnology Guide 2026

The “16th European Biotechnology Science & Industry Guide 2026” – the handbook will present the strengths and core competencies of companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing in Europe. Besides the printed version the guide will also be available as a digital version.

Read more
Discovery Center of AstraZeneca @AstraZeneca
M&A

AstraZeneca buys Chinese Gracell Biotechnologies for $1.2bn

Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.

Read more